rs397508470
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000492.4(CFTR):c.2989-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000685 in 1,460,502 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000492.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.2989-1G>A | splice_acceptor_variant, intron_variant | Intron 18 of 26 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251074Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135680
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460502Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726606
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:8
- -
The c.2989-1G>A variant in CFTR (also know as c.3121-1G>A) has been reported in several individuals with cystic fibrosis or congenital bilateral absence of the vas deferens (selected references: Feldmann 1998 PMID: 9452048, Casals 2000 PMID: 10875853, Alibakhshi 2008 PMID:17662673, Gaitch 2016 PMID: 27086061, Behar 2017 PMID: 28546993). It was absent from large population studies. This variant was classified as Pathogenic on Mar 17 2017 by the ClinGen-approved CFTR2 expert panel (Variation ID 53613). This variant occurs within the canonical splice site (+/- 1,2) and is predicted to cause altered splicing leading to an abnormal or absent protein. Loss of function of the CFTR gene is an established disease mechanism in autosomal recessive cystic fibrosis. In vitro functional studies provide some evidence that this variant impacts mRNA splicing (Sosnay 2013 PMID: 23974870) . In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive cystic fibrosis. ACMG/AMP Criteria applied: PM2_supporting, PM3_Very Strong, PS3_Supporting, PVS1. -
This sequence change affects an acceptor splice site in intron 18 of the CFTR gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is present in population databases (rs397508470, gnomAD 0.0009%). Disruption of this splice site has been observed in individuals with cystic fibrosis or congenital bilateral absence of the vas deferens (PMID: 9452048, 10875853, 17662673, 27086061, 28546993). This variant is also known as c.3121-1G>A. ClinVar contains an entry for this variant (Variation ID: 53613). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 23974870). For these reasons, this variant has been classified as Pathogenic. -
- -
The c.2989-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 19 of the CFTR gene. This mutation has been reported in multiple cystic fibrosis patients with a second mutation confirmed in trans and is associated with elevated sweat chloride levels and pancreatic insufficiency (Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
- -
- -
- -
not specified Pathogenic:1
Variant summary: The CFTR c.2989-1G>A variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict a significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 1/245874 control chromosomes (gnomAD) at a frequency of 0.0000041, which does not exceed the estimated maximal expected allele frequency of a pathogenic CFTR variant (0.0129603). This variant was found in multiple CF patients (Sosnay_2013, Behar_2017, Alibakhshi_2008). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic/likely pathogenic. Taken together, this variant is classified as pathogenic. -
CFTR-related disorder Pathogenic:1
- -
not provided Pathogenic:1
- -
Cystic fibrosis;C0238339:Hereditary pancreatitis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation;C2749757:Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
- -
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at